This company listing is no longer active
Calliditas Therapeutics Toekomstige groei
Future criteriumcontroles 6/6
Calliditas Therapeutics is forecast to grow earnings and revenue by 51.9% and 33.1% per annum respectively. EPS is expected to grow by 57.5% per annum. Return on equity is forecast to be 105.9% in 3 years.
Belangrijke informatie
51.9%
Groei van de winst
57.5%
Groei van de winst per aandeel
| Pharmaceuticals winstgroei | 24.1% |
| Inkomstengroei | 33.1% |
| Toekomstig rendement op eigen vermogen | 105.9% |
| Dekking van analisten | Good |
| Laatst bijgewerkt | 16 Aug 2024 |
Recente toekomstige groei-updates
Recent updates
Asahi Kasei To Pay A Fair Price For Calliditas Therapeutics
May 28Calliditas Therapeutics GAAP EPS of -SEK 3.62, revenue of SEK 64M
Aug 18Calliditas Therapeutics wins European approval for Kinpeygo for IgA nephropathy
Jul 15Calliditas submits nefecon marketing authorisation application to the EMA
May 28Calliditas shares rise 10% as FDA grants priority review for Nefecon
Apr 28Calliditas Therapeutics reports Q3 results
Nov 12Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2026 | 4,887 | 1,778 | 4,590 | 4,617 | 7 |
| 12/31/2025 | 3,387 | 1,019 | 1,703 | 1,735 | 9 |
| 12/31/2024 | 1,984 | -183 | 358 | 374 | 9 |
| 6/30/2024 | 1,601 | -480 | -258 | -245 | N/A |
| 3/31/2024 | 1,311 | -525 | -414 | -401 | N/A |
| 12/31/2023 | 1,207 | -466 | -447 | -435 | N/A |
| 9/30/2023 | 1,184 | -451 | -230 | -227 | N/A |
| 6/30/2023 | 1,150 | -292 | -292 | -290 | N/A |
| 3/31/2023 | 944 | -393 | -354 | -352 | N/A |
| 12/31/2022 | 803 | -412 | -314 | -311 | N/A |
| 9/30/2022 | 405 | -628 | -724 | -703 | N/A |
| 6/30/2022 | 343 | -608 | -634 | -611 | N/A |
| 3/31/2022 | 279 | -576 | -541 | -519 | N/A |
| 12/31/2021 | 229 | -500 | -484 | -462 | N/A |
| 9/30/2021 | 199 | -452 | -422 | -420 | N/A |
| 6/30/2021 | 0 | -600 | -490 | -490 | N/A |
| 3/31/2021 | 0 | -501 | -425 | -425 | N/A |
| 12/31/2020 | 1 | -433 | -309 | -309 | N/A |
| 9/30/2020 | 47 | -286 | -233 | -235 | N/A |
| 6/30/2020 | 47 | -198 | -64 | -48 | N/A |
| 3/31/2020 | 185 | -54 | -57 | -40 | N/A |
| 12/31/2019 | 185 | -33 | -87 | -71 | N/A |
| 9/30/2019 | 138 | -54 | -86 | -68 | N/A |
| 6/30/2019 | 138 | -35 | -166 | -166 | N/A |
| 3/31/2019 | N/A | -136 | -144 | -144 | N/A |
| 12/31/2018 | N/A | -132 | -128 | -128 | N/A |
| 9/30/2018 | N/A | -128 | -112 | -112 | N/A |
| 6/30/2018 | N/A | -115 | -114 | -114 | N/A |
| 3/31/2018 | N/A | -113 | N/A | -89 | N/A |
| 12/31/2017 | N/A | -87 | N/A | -68 | N/A |
| 12/31/2016 | N/A | -57 | N/A | -55 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: CALT is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.5%).
Winst versus markt: CALT is forecast to become profitable over the next 3 years, which is considered above average market growth.
Hoge groeiwinsten: CALT is expected to become profitable in the next 3 years.
Omzet versus markt: CALT's revenue (33.1% per year) is forecast to grow faster than the US market (8.7% per year).
Hoge groei-inkomsten: CALT's revenue (33.1% per year) is forecast to grow faster than 20% per year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: CALT's Return on Equity is forecast to be very high in 3 years time (105.9%).